The Italian National Research Council (CNR) has declared that no commercially available devices currently exist for patients who are physically unable to self-administer lethal medication under medically assisted death procedures, a statement that underscores a critical gap in the country's evolving end-of-life legal framework.
Why This Matters:
• No off-the-shelf solutions: Immobilized patients seeking medically assisted death face technological barriers, as devices must be custom-built on a case-by-case basis.
• Legal limbo continues: Italy's Parliament is still debating comprehensive end-of-life legislation, leaving regional health authorities and courts to navigate requests without clear national guidelines.
• Cost and responsibility unclear: The case that prompted CNR's testimony shows health services bearing production costs for bespoke devices, raising questions about future accessibility and equity.
Senate Hearing Reveals Technology Void
CNR President Andrea Lenzi made the disclosure during testimony before the Italian Senate's Justice and Social Affairs committees today, as lawmakers consider draft legislation on end-of-life care. His remarks came in response to questions about whether the research institution—Italy's principal public research body—could develop or supply assistive devices for patients unable to physically activate medication delivery systems.
"At present, the presidency of the institution is not aware of any commercially available or feasible instruments for the self-administration of drugs that could be employed in medically assisted death procedures for immobilized or incapacitated persons, nor are there any related projects under study," Lenzi stated. The assertion highlights a practical obstacle that could affect dozens of terminally ill patients annually who meet legal criteria but lack the physical capability to complete the final act themselves.
The Precedent: Libera's Eye-Tracking Device
Lenzi referenced the case of a 55-year-old Tuscan woman, known publicly as "Libera," whose two-year legal battle concluded in March 2026 when she died at home using a prototype eye-tracking activation system. Libera, who suffered from multiple sclerosis and spastic quadriplegia, had filed her request with the ASL Toscana Nord Ovest health authority in March 2024. Her initial application was rejected because she had refused a feeding tube, which medical reviewers claimed disqualified her from meeting the "life-sustaining treatment" criterion outlined in landmark Constitutional Court rulings.
Supported by the Luca Coscioni Association, Libera escalated the matter to the Florence Tribunal, which in October 2025 ordered the health authority to provide necessary drugs and equipment within 15 days. The court explicitly mandated delivery of a device controllable via eye movement. A month later, the tribunal issued a separate order directing the CNR itself to design and produce the apparatus within 90 days. The ASL Toscana Nord Ovest absorbed all manufacturing costs, though no public figure has been disclosed.
The device was delivered in March 2026, and Libera used it to self-administer the lethal medication on March 25, becoming the first person in Italy to access medically assisted death through ocular-command technology.
CNR's Role Under Scrutiny
Lenzi used the hearing to clarify the institutional limits of the CNR's mandate. "The potential commercialization of such a device, regardless of need, would presuppose that CNR operates with productive or product-marketing objectives, rather than as an entity whose primary function is scientific research," he explained. The remark suggests resistance within the council to becoming a de facto medical device manufacturer, even as courts increasingly turn to public research institutions when private industry has no solution.
The CNR prototype was developed by a single employee acting under direct judicial authorization, a model the institution's leadership considers unsustainable and outside its statutory mission. Without a national law defining responsibility for such devices—or funding mechanisms to support their production—health authorities, research bodies, and courts are improvising solutions case by case.
What This Means for Residents
For Italians living with terminal illness or irreversible conditions who wish to explore medically assisted death, the CNR testimony reveals several immediate implications:
Access remains geographically uneven. While Tuscany enacted regional guidelines in February 2025, other regions have not followed suit. Patients outside Tuscany may face longer delays or outright refusals, particularly if they require assistive technology.
Costs and delays are unpredictable. With no standardized devices, each request that involves physical disability may require bespoke engineering, tribunal intervention, and uncertain timelines. Libera's process took two years and involved multiple court orders.
Legal clarity is absent. Italy's current framework derives from Constitutional Court rulings in 2019 and 2024, which decriminalized assisted suicide under specific conditions: the patient must be capable of decision-making, suffer from an irreversible pathology causing intolerable physical or psychological distress, and be sustained by life-support treatments. Yet the court decisions did not address the practical mechanics of self-administration for those physically unable to perform it, leaving judges to fill the void.
Legislative Stalemate Persists
The draft bill under Senate review has been stalled for years amid deep political divisions. A unified text proposed by Senator Alfredo Bazoli of the Democratic Party serves as the opposition's reference point, but the governing majority has sought to send the bill back to committee, arguing it extends beyond Constitutional Court guidance and amounts to "euthanasia" rather than assisted suicide—a distinction with profound legal and ethical weight.
Some lawmakers from the center-right coalition contend that allowing third parties to activate devices crosses the line into active euthanasia, which remains illegal in Italy. Others maintain that technological assistance for self-administration preserves the patient's autonomous act, satisfying constitutional requirements. The debate hinges not just on philosophy but on who presses the button—or, in Libera's case, where the patient's gaze falls.
European Context: Italy Lags on Clarity
Across the EU, several countries have codified medically assisted death, though specific provisions for assistive devices remain rare in public documentation. Belgium, the Netherlands, Luxembourg, Spain, Austria, Portugal, and Switzerland all permit some form of assisted dying, with varying eligibility criteria and procedural safeguards. Germany's Constitutional Court struck down bans on organized assistance in 2020, affirming self-determination rights, but implementing legislation is still under negotiation.
None of these frameworks explicitly detail technical solutions for patients with severe mobility impairments, focusing instead on medical protocols, eligibility, and oversight. Italy's experience with Libera may be among the first in Europe to force judicial and institutional reckoning with the intersection of advanced disability and end-of-life autonomy.
Outlook: Courts, Not Commerce
Unless Parliament passes comprehensive legislation—or the private medical device sector develops commercial solutions—Italy's path forward will likely remain court-driven and regionally fragmented. Health authorities and research institutions may face additional judicial orders, each requiring ad hoc engineering and cost allocation. For patients, this means continued uncertainty, protracted legal processes, and outcomes dependent on where they live and which tribunal hears their case.
The CNR's testimony today signals reluctance from the scientific establishment to assume a manufacturing role without legislative cover. Whether that pressure will finally compel lawmakers to resolve years of deadlock remains to be seen.
